



DRUG DISCOVERY

## **Advances in the Stem Cell Industry**

The future impact of innovation, and an evaluation of the commercial landscape

By Paul Evers

## **Paul Evers**

Paul Evers is a market research consultant and writer, specializing in the pharmaceutical and medical industries. During the past 20 years he has researched and written detailed studies on a wide range of pharmaceutical and medical market sectors including the stem cell industry. Prior to becoming a full-time consultant he worked as director of marketing for Elan Corporation. He studied medical sciences at the National University of Ireland and holds an honors degree in biological sciences and humanities from The Open University

Copyright © 2009 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Advances in the Stem Cell Industry

<b>Executive summary</b>	<b>10</b>	
Background	10	
Stem cell research and development: scope and status	10	
Commercial landscape	11	
Industry landscape	12	
<b>Chapter 1</b>	<b>Background</b>	<b>16</b>
Summary		16
<b>Introduction</b>		<b>17</b>
The building blocks of life		17
<b>About stem cells</b>		<b>18</b>
Potency		20
Stem cell division		21
Stem cell research		21
Human ESCs		23
<b>Current status of knowledge</b>		<b>24</b>
Embryonic stem cells		24
Growth and identification of ESCs		25
Stimulating ESCs to differentiate		26
Adult stem cells		26
Cord blood stem cells		29
Induced pluripotent stem cells		30
Nuclear reprogramming		31
Ethical and regulatory issues		33
Situation in the US		33
European regulations		34
<b>Chapter 2</b>	<b>Stem cell research and development: scope and status</b>	<b>38</b>
Summary		38

<b>Introduction</b>	<b>39</b>
<b>Practical applications of stem cells</b>	<b>39</b>
Disease treatment	40
Amyotrophic lateral sclerosis	40
Parkinson's disease	43
Spinal cord injury	44
Alzheimer's disease	46
Cancer	48
Heart disease	49
Peripheral arterial disease	52
Type 1 diabetes	55
Liver failure	59
Graft-versus-host disease	60
Stem cell models: applications in drug discovery	61
Screening studies	61
Toxicity studies	63
Practical benefits	64
Some skepticism remains	65
<b>Chapter 3</b>	<b>Commercial landscape</b>
	<b>68</b>
<b>Summary</b>	<b>68</b>
<b>Resisting the hyperbole</b>	<b>69</b>
<b>Market realities</b>	<b>70</b>
Cell-based therapy market	70
Autologous SC therapy	71
Allogeneic SC therapy	71
Cord blood banks	71
Market drivers	72
Market	73
<b>Global market estimates and forecasts</b>	<b>74</b>
Global market by use	75
Global market by country share	76
Embryo vs. adult stem cells	77
Investment opportunities	78
Choosing a viable business model	79
Matching the model to the circumstance	80
Autologous therapy models	80
Allogeneic therapy models	83
<b>Chapter 4</b>	<b>Industry landscape</b>
	<b>86</b>
<b>Summary</b>	<b>86</b>
<b>Introduction</b>	<b>87</b>

<b>Company profiles</b>	<b>89</b>
Aastrom Biosciences, Inc.	89
Overview	89
Pipeline	90
Advanced Cell Technology, Inc.	90
Overview	91
Pipeline	91
Collaboration	92
Aldagen	92
Overview	92
Pipeline	92
Collaboration	93
Angioblast Systems, Inc.	93
Overview	93
Pipeline	94
Athersys, Inc.	95
Overview	95
Pipeline	95
Collaboration	96
Financials	96
Bioheart, Inc.	97
Overview	97
Pipeline	97
Bionet	98
Overview	99
Collaboration	99
Brainstorm Cell Therapeutics	99
Overview	100
Capricor, Inc.	101
Overview	101
Pipeline	101
Collaboration	102
Cardio3 BioSciences SA	102
Overview	102
Cellcyte Genetics	103
Overview	103
Pipeline	103
Collaboration	104
Cellerix SA	104
Overview	104
Pipeline	105
CellGenix Technologie Transfer	105
Overview	106
Cytori Therapeutics, Inc.	107
Overview	107
Entest BioMedical, Inc.	107
Overview	108
ES Cell International	108
Overview	109
EvoStem Finland Oy	109
Overview	110

Fate Therapeutics, Inc.		110
	Overview	110
Genzyme		112
	Collaboration	113
	Financials	113
Geron		113
	Overview	113
	Pipeline	114
Healthuniverse, Inc.		114
	Overview	115
Innovacell Biotechnologie AG		115
	Overview	116
International Stem Cell Corporation (ISCO)		116
	Overview	116
	Financing	118
iPierian, Inc.		118
	Overview	118
Ixion Biotechnology, Inc.		119
	Overview	119
Karocell Tissue Engineering AB		120
	Overview	120
MedCell Bioscience Ltd		121
	Overview	121
MediStem, Inc.		122
	Overview	122
	Pipeline	123
Mesoblast Limited		124
	Overview	125
Nephrogenix		126
	Overview	126
Neuralstem, Inc.		127
	Overview	127
	Pipeline	128
	Collaboration	128
OncoStem Pharma		128
	Overview	128
Novocell, Inc.		129
	Overview	129
NuVasive, Inc.		130
	Overview	130
Osiris Therapeutics, Inc.		131
	Overview	131
	Pipeline	131
	Collaboration	132
	Financials	133
Pharmicell Europe GmbH		133
	Overview	133
PrimeGen Biotech		134
	Overview	135
Opexa Therapeutics		136
	Overview	136

	Financing	136
	Financials	137
Plureon		137
	Overview	137
	Pipeline	138
	Collaboration	138
Proteonomix, Inc.		139
	Overview	139
Regenerative Sciences, Inc.		140
	Overview	140
ReNeuron		140
	Overview	141
	Pipeline	141
Shenzhen Beike		143
	Overview	143
Stematix, Inc.		143
	Overview	144
StemCells, Inc.		145
	Overview	145
Stem Cell Therapeutics		146
	Overview	147
Stem Cell Therapy International		147
	Overview	147
Stemedica Cell Technologies, Inc.		148
	Overview	148
Stempeutics Research Pvt. Ltd.		149
	Overview	150
t2cure GmbH		150
	Overview	151
TICEBA GmbH		152
	Overview	152
Tristem		153
	Overview	153

## **Chapter 5                      Appendix                      154**

<b>Methodology</b>	<b>154</b>
<b>Glossary</b>	<b>155</b>
<b>Index</b>	<b>162</b>

# List of Figures

Figure 1.1:	Early embryonic development and later differentiation	19
Figure 1.2:	Stem cell division	21
Figure 1.3:	Induced pluripotent stem cells	31
Figure 2.4:	Stem cell opportunities in disease treatment and R&D	40
Figure 3.5:	Forces affecting the stem cell market	73
Figure 3.6:	Key challenges faced when developing autologous therapy	83
Figure 4.7:	Type and number of regenerative medicine organizations	87

# List of Tables

Table 3.1:	Global stem cell market (\$m), 2008-14	74
Table 3.2:	Potential US patient populations for cell-based therapies	75
Table 3.3:	Stem cell market by main uses (\$m), 2008-14	76
Table 3.4:	Country breakdown of stem cell market (\$m), 2008-14	77
Table 3.5:	Leading cell-based regenerative medicine products	79